HOOKIPA Pharma Statistics
Total Valuation
HOOKIPA Pharma has a market cap or net worth of $61.99 million. The enterprise value is -$24.68 million.
| Market Cap | 61.99M |
| Enterprise Value | -24.68M |
Important Dates
The next estimated earnings date is Thursday, August 8, 2024, before market open.
| Earnings Date | Aug 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HOOKIPA Pharma has 9.66 million shares outstanding. The number of shares has increased by 80.82% in one year.
| Shares Outstanding | 9.66M |
| Shares Change (YoY) | +80.82% |
| Shares Change (QoQ) | +17.87% |
| Owned by Insiders (%) | 19.59% |
| Owned by Institutions (%) | 41.53% |
| Float | 5.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.16 |
| Forward PS | n/a |
| PB Ratio | 0.59 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.50, with a Debt / Equity ratio of 0.06.
| Current Ratio | 4.50 |
| Quick Ratio | 4.19 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -239.37 |
Financial Efficiency
Return on equity (ROE) is -47.30% and return on invested capital (ROIC) is -57.80%.
| Return on Equity (ROE) | -47.30% |
| Return on Assets (ROA) | -28.70% |
| Return on Capital (ROIC) | -57.80% |
| Revenue Per Employee | $299,173 |
| Profits Per Employee | -$265,458 |
| Employee Count | 179 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HOOKIPA Pharma has paid $164,000 in taxes.
| Income Tax | 164,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.62% in the last 52 weeks. The beta is 0.80, so HOOKIPA Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.80 |
| 52-Week Price Change | -27.62% |
| 50-Day Moving Average | 7.26 |
| 200-Day Moving Average | 6.79 |
| Relative Strength Index (RSI) | 49.01 |
| Average Volume (20 Days) | 57,732 |
Short Selling Information
The latest short interest is 647,781, so 6.71% of the outstanding shares have been sold short.
| Short Interest | 647,781 |
| Short Previous Month | 453,041 |
| Short % of Shares Out | 6.71% |
| Short % of Float | 12.72% |
| Short Ratio (days to cover) | 1.20 |
Income Statement
In the last 12 months, HOOKIPA Pharma had revenue of $53.55 million and -$47.52 million in losses. Loss per share was -$5.00.
| Revenue | 53.55M |
| Gross Profit | 53.55M |
| Operating Income | -63.93M |
| Pretax Income | -47.35M |
| Net Income | -47.52M |
| EBITDA | -43.89M |
| EBIT | -47.16M |
| Loss Per Share | -$5.00 |
Balance Sheet
The company has $92.75 million in cash and $6.08 million in debt, giving a net cash position of $86.67 million or $8.98 per share.
| Cash & Cash Equivalents | 92.75M |
| Total Debt | 6.08M |
| Net Cash | 86.67M |
| Net Cash Per Share | $8.98 |
| Equity (Book Value) | 104.52M |
| Book Value Per Share | 10.83 |
| Working Capital | 103.20M |
Cash Flow
In the last 12 months, operating cash flow was -$78.83 million and capital expenditures -$4.00 million, giving a free cash flow of -$82.83 million.
| Operating Cash Flow | -78.83M |
| Capital Expenditures | -4.00M |
| Free Cash Flow | -82.83M |
| FCF Per Share | -$8.37 |
Margins
Gross margin is 100.00%, with operating and profit margins of -119.38% and -88.73%.
| Gross Margin | 100.00% |
| Operating Margin | -119.38% |
| Pretax Margin | -88.42% |
| Profit Margin | -88.73% |
| EBITDA Margin | -81.95% |
| EBIT Margin | -88.06% |
| FCF Margin | -154.68% |
Dividends & Yields
HOOKIPA Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -80.82% |
| Shareholder Yield | -80.82% |
| Earnings Yield | -76.66% |
| FCF Yield | -133.63% |
Analyst Forecast
The average price target for HOOKIPA Pharma is $50.00, which is 678.82% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $50.00 |
| Price Target Difference | 678.82% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 58.88% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 10, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
HOOKIPA Pharma has an Altman Z-Score of -2.36 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.36 |
| Piotroski F-Score | 2 |